文献速递前列腺癌

阴性确认性MRI-超声融合活检对前列腺癌主动监测中Gleason分组进展的预测作用

Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: Role of a Negative Confirmatory Magnetic Resonance Imaging-Ultrasound Fusion Biopsy.
PubMed 文献 · J Urol · 2019-01-01

本研究纳入542例在外院系统活检诊断为Gleason分组1或2的前列腺癌患者,均接受确认性融合活检。111例(20.5%)融合活检阴性。中位随访中,阴性组60例与阳性组122例继续主动监测,至Gleason分组进展的中位时间分别为74.3个月和44.6个月(p<0.01)。阴性融合活检与Gleason分组进展风险降低相关(HR 0.41,95%CI 0.22-0.77,p<0.01)。

要点

  • 确认性融合活检阴性者Gleason分组进展风险显著降低(HR 0.41)。
  • 阴性组至进展中位时间74.3个月,阳性组44.6个月。
  • 阴性融合活检结果可用于咨询进展风险和规划随访。

核心结论

  • 阴性确认性融合活检提示Gleason分组进展预后良好,可用于患者咨询和随访规划。

研究设计与样本

  • 回顾性队列研究,纳入542例外院系统活检诊断为Gleason分组1(466例)或2(76例)的前列腺癌患者,均接受确认性融合活检(扩展六分区系统活检+MRI可疑病灶靶向活检)。

主要发现

  • 111例(20.5%)确认性融合活检阴性。
  • 阴性组60例与阳性组122例继续主动监测,至Gleason分组进展中位时间分别为74.3个月和44.6个月(p<0.01)。
  • 阴性融合活检与Gleason分组进展风险降低相关(HR 0.41,95%CI 0.22-0.77,p<0.01)。

临床怎么用

  • 对主动监测患者,阴性确认性融合活检结果可用于咨询Gleason分组进展风险并规划后续随访和活检。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Active surveillance has gained acceptance as an alternative to definitive therapy in many men with prostate cancer. Confirmatory biopsies to assess the appropriateness of active surveillance are routinely performed and negative biopsies are regarded as a favorable prognostic indicator. We sought to determine the prognostic implications of negative multiparametric magnetic resonance imaging-transrectal ultrasound guided fusion biopsy consisting of extended sextant, systematic biopsy plus multiparametric magnetic resonance imaging guided targeted biopsy of suspicious lesions on magnetic resonance imaging. MATERIALS AND METHODS: All patients referred with Gleason Grade Group 1 or 2 prostate cancer based on systematic biopsy performed elsewhere underwent confirmatory fusion biopsy. Patients who continued on active surveillance after a positive or a negative fusion biopsy were followed. The baseline characteristics of the biopsy negative and positive cases were compared. Cox regression analysis was used to determine the prognostic significance of a negative fusion biopsy. Kaplan-Meier survival curves were used to estimate Grade Group progression with time. RESULTS: Of the 542 patients referred with Grade Group 1 (466) or Grade Group 2 (76) cancer 111 (20.5%) had a negative fusion biopsy. A total of 60 vs 122 patients with a negative vs a positive fusion biopsy were followed on active surveillance with a median time to Grade Group progression of 74.3 and 44.6 months, respectively (p <0.01). Negative fusion biopsy was associated with a reduced risk of Grade Group progression (HR 0.41, 95% CI 0.22-0.77, p <0.01). CONCLUSIONS: A negative confirmatory fusion biopsy confers a favorable prognosis for Grade Group progression. These results can be used when counseling patients about the risk of progression and for planning future followup and biopsies in patients on active surveillance.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Bloom JB, Hale GR, Gold SA, et al. Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: Role of a Negative Confirmatory Magnetic Resonance Imaging-Ultrasound Fusion Biopsy. J Urol. 2019. PMID: 30577395. doi:10.1016/j.juro.2018.07.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。